These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22170343)

  • 21. Role of the myristoylation site in expressing exogenous functional proteins in coxsackieviral vector.
    Lim BK; Yun SH; Ju ES; Gil CO; Kim DK; Jeon ES
    Biosci Biotechnol Biochem; 2012; 76(6):1173-6. PubMed ID: 22790942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
    Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
    Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of short hairpin RNAs against the coxsackievirus B3 exerts potential antiviral effects in Cos-7 cells and in mice.
    Kim JY; Chung SK; Hwang HY; Kim H; Kim JH; Nam JH; Park SI
    Virus Res; 2007 Apr; 125(1):9-13. PubMed ID: 17222937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.
    Pinkert S; Westermann D; Wang X; Klingel K; Dörner A; Savvatis K; Grössl T; Krohn S; Tschöpe C; Zeichhardt H; Kotsch K; Weitmann K; Hoffmann W; Schultheiss HP; Spiller OB; Poller W; Fechner H
    Circulation; 2009 Dec; 120(23):2358-66. PubMed ID: 19933937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia.
    Ohara N; Koyama H; Miyata T; Hamada H; Miyatake SI; Akimoto M; Shigematsu H
    Gene Ther; 2001 Jun; 8(11):837-45. PubMed ID: 11423931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
    Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
    J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand.
    Yuan J; Cheung PK; Zhang HM; Chau D; Yang D
    J Virol; 2005 Feb; 79(4):2151-9. PubMed ID: 15681418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector.
    Byun J; Heard JM; Huh JE; Park SJ; Jung EA; Jeong JO; Gwon HC; Kim DK
    J Mol Cell Cardiol; 2001 Feb; 33(2):295-305. PubMed ID: 11162134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
    Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
    J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3.
    Chapman NM; Romero JR; Pallansch MA; Tracy S
    J Med Virol; 1997 Jul; 52(3):258-61. PubMed ID: 9210033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation.
    Chandler LA; Doukas J; Gonzalez AM; Hoganson DK; Gu DL; Ma C; Nesbit M; Crombleholme TM; Herlyn M; Sosnowski BA; Pierce GF
    Mol Ther; 2000 Aug; 2(2):153-60. PubMed ID: 10947943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant polymer-protein fusion: a promising approach towards efficient and targeted gene delivery.
    Hatefi A; Megeed Z; Ghandehari H
    J Gene Med; 2006 Apr; 8(4):468-76. PubMed ID: 16416505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IRES-based vector coexpressing FGF2 and Cyr61 provides synergistic and safe therapeutics of lower limb ischemia.
    Rayssac A; Neveu C; Pucelle M; Van den Berghe L; Prado-Lourenco L; Arnal JF; Chaufour X; Prats AC
    Mol Ther; 2009 Dec; 17(12):2010-9. PubMed ID: 19738600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer.
    Cai L; Liu Z
    Cancer Med; 2020 Jul; 9(14):5210-5220. PubMed ID: 32459400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Echovirus plays major roles in the natural recombination of Coxsackievirus B3.
    Shen H; Liu T; Luo Y; Shao S; Deng X; Wang H
    J Med Virol; 2018 Feb; 90(2):377-382. PubMed ID: 28851122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.
    Miller JP; Geng Y; Ng HL; Yang OO; Krogstad P
    Vaccine; 2009 Jun; 27(30):3992-4000. PubMed ID: 19389440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Bahreyni A; Liu H; Mohamud Y; Xue YC; Zhang J; Luo H
    Cancer Lett; 2022 Nov; 548():215849. PubMed ID: 35995138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Title: Gene transfer by pyro-drive jet injector is a novel therapeutic approach for muscle diseases.
    Nakae T; Obana M; Maeda T; Ikeda A; Miyazaki H; Tanaka S; Maeda M; Yamashita K; Terai K; Obika S; Fujio Y
    Gene; 2021 Jul; 788():145664. PubMed ID: 33887371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice.
    Liu D; Buluwela L; Ali S; Thomson S; Gomm JJ; Coombes RC
    Eur J Cancer; 2001 Jan; 37(2):268-80. PubMed ID: 11166156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
    Liu H; Xue YC; Deng H; Mohamud Y; Ng CS; Chu A; Lim CJ; Lockwood WW; Jia WWG; Luo H
    Mol Ther Oncolytics; 2020 Mar; 16():207-218. PubMed ID: 32123721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.